Investigative product portfolio

Our Global Internal Discovery Pipeline Covers the Vast Majority of the World’s Cancers^1-3

One of the world’s largest oncology research teams (3000+ global clinical team members) with 50+ assets in clinical and commercialization stages

Solid Tumors

Breast cancer

BGB-43395 CDK4

Phase 1: Breast cancer

BG-68501^* CDK2

Phase 1: Breast cancer

BG-C9074^† B7H4-ADC

Phase 1: Breast cancer

Zanidatamab^‡ HER2 BsAb

Phase 1: 1L metastatic breast cancer

Goserelin microspheres^§ GnRH agonist

Phase 3: Breast cancer

Esophageal cancer
Gastric cancer

Zanidatamab^‡ HER2 BsAb

Phase 1: Gastric cancer
Phase 3: 1L HER2+ GEA

LBL-007^|| LAG3

Phase 2: 1L ESCC

Tislelizumab PD-1

Phase 3: Locally advanced ESCC
Registration studies (US only): 1L gastric cancer/GEJC; 1L ESCC

Colorectal cancer

LBL-007^|| LAG3

Phase 2: MSS-CRC

Prostate cancer

Xaluritamig^¶ STEAP1 x CD3

Phase 1: mCRPC (initiation activities)

Goserelin microspheres^§ GnRH agonist

Phase 3: Prostate cancer

Non–small cell lung cancer
Small cell lung cancer

Ociperlimab TIGIT

Phase 2: 1L NSCLC
Phase 3: 1L NSCLC PD-L1 high

Tislelizumab PD-1

Phase 1: NSCLC (subcutaneous formulation)
Phase 2: 1L NSCLC, 2L+ NSCLC, neoadjuvant NSCLC (umbrella study)^4,#
Phase 3: Neo/adjuvant NSCLC^**
Phase 3: 1L nonsquamous NSCLC, 1L squamous NSCLC, 2L+ NSCLC
Phase 3: 1L ES-SCLC

Tarlatamab^¶ DLL3 x CD3

Phase 3: 2L SCLC, 1L ES-SCLC (initiation activities), LS-SCLC (initiation activities), 3L+ SCLC

Other solid tumors/
disease states

BGB-A445 OX40

Phase 2: Melanoma, RCC, urothelial carcinoma

Tislelizumab PD-1

Phase 2: 1L HNSCC (umbrella study)^5,#
Phase 3: 1L HCC, 2L+ HCC
Phase 3: 1L NPC
Phase 3: 1L UBC

Zanidatamab^‡ HER2 BsAb

Phase 2: HER2+ 2L BTC

Pamiparib PARP

Phase 2: Advanced ovarian cancer
Phase 3: 2L methotrexate gBRCAm PSOC

Surzebiclimab TIM-3

Phase 2: 1L HNSCC

Blinatumomab^¶ CD3 x CD19

Phase 2: Pediatric R/R BP-ALL (initiation activities)

Additional investigational
products (solid tumors)

Ociperlimab TIGIT

Phase 1: Solid tumors

BGB-15025/26808 HPK1

Phase 1: Solid tumors

BGB-30813 DGKζ

Phase 1: Solid tumors

BGB-A3055 CCR8

Phase 1: Solid tumors

BGB-24714 SMAC mimetic

Phase 1: Solid tumors

BGB-10188 PI3Kδ

Phase 1: Solid tumors

BGB-43395 CDK4

Phase 1: Solid tumors

BG-68501^* CDK2

Phase 1: Solid tumors

BG-C9074^† B7H4-ADC

Phase 1: Solid tumors

Hematology

Non-Hodgkin lymphoma

Zanubrutinib BTK

Phase 2: Previously treated B-cell malignancies
Phase 2: CD79B R/R DLBCL
Phase 2: R/R MCL
Phase 3: TN MCL
Phase 3: R/R MZL, R/R FL, WM, CLL/SLL
Registration study (US only): R/R CLL/SLL (PFS)

Sonrotoclax BCL-2

Phase 2: R/R MCL
Phase 2: R/R CLL
Phase 2: R/R WM
Phase 3: TN CLL^††

Ociperlimab TIGIT

Phase 1: R/R DLBCL

BGB-16673 BTK CDAC

Phase 2: R/R MCL, R/R CLL

B-cell malignancies

Sonrotoclax BCL-2

Phase 1: B-cell malignancies

BGB-16673 BTK CDAC

Phase 1: B-cell malignancies

BGB-21447 next-gen BCL-2

Phase 1: B-cell malignancies

Other hematologic malignancies

Sonrotoclax BCL-2

Phase 1: AML/MDS
Phase 1: R/R MM with t(11;14)

Hodgkin lymphoma

Tislelizumab PD-1

Phase 3: R/R cHL

Non-oncology

Inflammation and immunology

Zanubrutinib BTK

Phase 2: Lupus nephritis
Phase 3: Primary membranous nephropathy

Safety and efficacy have not been established for investigational products and/or uses.

Registration includes select accepted submissions.

Portfolio as of May 2024.

Abbreviations: 1L, first-line; 2L, second-line; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; APAC, Asia–Pacific; BCL-2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, C-C chemokine receptor 8; CD, cluster of differentiation; CDAC, chimeric degradation activating compound; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classic Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase zeta; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; ES, extensive-stage; ESCC, esophageal squamous cell carcinoma; FL, follicular lymphoma; gBRCAm, germline BRCA-mutated; GEA, gastroesophageal adenocarcinoma; GEJC, gastroesophageal junction carcinoma; GnRH, gonadotropin-releasing hormone; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; LAG3, lymphocyte activation gene 3; LS, limited-stage; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stable; MUC1, mucin 1; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NSCLC, non–small cell lung cancer; PARP, poly (ADP-ribose) polymerase; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; PI3Kδ, phosphoinositide 3-kinase delta; PSOC, platinum-sensitive ovarian cancer; RCC, renal cell carcinoma; R/R, relapsed/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, 6-transmembrane epithelial antigen of the prostate 1; TIGIT, T-cell immunoreceptor with immunoglobulin and ITIM domains; TIM-3, T-cell immunoglobulin and mucin domain-containing protein 3; TN, treatment naive; UBC, urothelial bladder cancer; WM, Waldenström macroglobulinemia.

^*Ensem collaboration; BeiGene has global rights.

^†DualityBio collaboration; BeiGene has global rights.

^‡Zymeworks/Jazz collaboration; BeiGene has APAC/ex-Japan, Australia, and New Zealand commercial rights.

^§Luye collaboration; BeiGene has China rights.

^||Leads Biolabs collaboration; BeiGene has ex-China commercial rights.

^¶Amgen collaboration; BeiGene has China commercial rights.

^#The umbrella study is a phase 2 study of tislelizumab as monotherapy and in combination with ociperlimab and LBL-007 as neoadjuvant treatment for resectable NSCLC. The umbrella trial design allows for multiple investigational drugs, administered alone or in combination, in a single disease population.²

^**Primary endpoint met.

^††In combination with zanubrutinib.

References: 1. BeiGene Corporate Presentation. January 8, 2024. 2. BeiGene. Solid tumor pipeline. Accessed June 12, 2024. https://beigenevirtualexperience.com/medicalaffairs/static/content/content/clinical_pipelipi/pdf/Pipeline%20Screen_Solid%20Tumor.pdf?202406 3. BeiGene. Hematology pipeline. Accessed June 12, 2024. https://beigenevirtualexperience.com/medicalaffairs/static/content/content/clinical_pipeline/pdf/Pipeline%20Screen_Hematology.pdf?202406 4. He J, Zhang P, Liu H, et al. BGB-LC-202 (NCT05577702): phase 2 umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC). Poster presented at the European Society for Medical Oncology (ESMO) Asia Congress; December 1-3, 2023; Singapore, Republic of Singapore. 5. Tislelizumab in combination with investigational agents in participants with head and neck squamous cell carcinoma. ClinicalTrials.gov identifier: NCT05909904. Accessed April 19, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05909904

You are now leaving BeiGeneEngage.com

Investigative product portfolio

Our Global Internal Discovery Pipeline Covers the Vast Majority of the World’s Cancers1-3

One of the world’s largest oncology research teams (3000+ global clinical team members) with 50+ assets in clinical and commercialization stages

Solid Tumors

Breast cancer

Esophageal cancer Gastric cancer

Colorectal cancer

Prostate cancer

Non–small cell lung cancer Small cell lung cancer

Other solid tumors/ disease states

Additional investigational products (solid tumors)

Hematology

Non-Hodgkin lymphoma

B-cell malignancies

Other hematologic malignancies

Hodgkin lymphoma

Non-oncology

Inflammation and immunology

You are now leaving BeiGeneEngage.com

Our Global Internal Discovery Pipeline Covers the Vast Majority of the World’s Cancers^1-3

Esophageal cancer
Gastric cancer

Non–small cell lung cancer
Small cell lung cancer

Other solid tumors/
disease states

Additional investigational
products (solid tumors)